LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 10 of 15: Cell count and normalized growth rate inhibition values within biological replicate 3. - Dataset - HMS LINCS Database

LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 10 of 15: Cell count and normalized growth rate inhibition values within biological replicate 3. - Dataset (ID:20247)

Download: Excel (XLSX), Comma-separated (CSV)

<<<<

Select the entities to show:

Small molecules	Cells

|<
<<
Previous
Page 271 of 535
Next
>>
>
6751 to 6775 of 13356 records
per page:

Cell	Small Molecule	Small Mol Concentration	Small Mol Conc Unit	LJP Library Plate	Replicate	Assay Well	Timepoint	Timepoint Unit	Total Cell Count Before Treatment	Total Cell Count After Treatment	Total Control Cell Count	Relative Cell Count	Normalized Growth Rate Inhibition Value
BT-20	Sorafenib	0.04	uM	LJP6	1	B12	72	hr	1097	3425	3610	0.9486	0.9395
BT-20	Sorafenib	0.04	uM	LJP6	2	B12	72	hr	1097	3511	3713	0.9454	0.9372
BT-20	Sorafenib	0.04	uM	LJP6	3	B12	72	hr	1097	3299	3696	0.8925	0.8743
BT-20	Sorafenib	0.12	uM	LJP6	1	B11	72	hr	1097	3657	3610	1.0129	1.0149
BT-20	Sorafenib	0.12	uM	LJP6	2	B11	72	hr	1097	3551	3713	0.9562	0.9497
BT-20	Sorafenib	0.12	uM	LJP6	3	B11	72	hr	1097	3253	3696	0.8800	0.8593
BT-20	Sorafenib	0.37	uM	LJP6	1	B10	72	hr	1097	3202	3610	0.8868	0.8650
BT-20	Sorafenib	0.37	uM	LJP6	2	B10	72	hr	1097	3286	3713	0.8848	0.8656
BT-20	Sorafenib	0.37	uM	LJP6	3	B10	72	hr	1097	2662	3696	0.7202	0.6583
BT-20	Sorafenib	1.11	uM	LJP6	1	B09	72	hr	1097	3050	3610	0.8447	0.8130
BT-20	Sorafenib	1.11	uM	LJP6	2	B09	72	hr	1097	3142	3713	0.8461	0.8187
BT-20	Sorafenib	1.11	uM	LJP6	3	B09	72	hr	1097	3082	3696	0.8338	0.8029
BT-20	Sorafenib	3.33	uM	LJP6	1	B08	72	hr	1097	3211	3610	0.8893	0.8681
BT-20	Sorafenib	3.33	uM	LJP6	2	B08	72	hr	1097	3037	3713	0.8178	0.7839
BT-20	Sorafenib	3.33	uM	LJP6	3	B08	72	hr	1097	3084	3696	0.8343	0.8036
BT-20	Sorafenib	10	uM	LJP6	1	B07	72	hr	1097	1236	3610	0.3423	0.0718
BT-20	Sorafenib	10	uM	LJP6	2	B07	72	hr	1097	1510	3713	0.4066	0.1991
BT-20	Sorafenib	10	uM	LJP6	3	B07	72	hr	1097	1238	3696	0.3349	0.0713
BT-20	CP466722	0.04	uM	LJP5	1	I12	72	hr	1097	4205	3735	1.1258	1.1387
BT-20	CP466722	0.04	uM	LJP5	2	I12	72	hr	1097	4118	3877	1.0619	1.0671
BT-20	CP466722	0.04	uM	LJP5	3	I12	72	hr	1097	4015	3925	1.0228	1.0247
BT-20	CP466722	0.12	uM	LJP5	1	I11	72	hr	1097	4211	3735	1.1274	1.1404
BT-20	CP466722	0.12	uM	LJP5	2	I11	72	hr	1097	3735	3877	0.9632	0.9592
BT-20	CP466722	0.12	uM	LJP5	3	I11	72	hr	1097	4200	3925	1.0699	1.0749
BT-20	CP466722	0.37	uM	LJP5	1	I10	72	hr	1097	3966	3735	1.0618	1.0690

|<
<<
Previous
Page 271 of 535
Next
>>
>
6751 to 6775 of 13356 records
per page:

HMS LINCS Project

LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 10 of 15: Cell count and normalized growth rate inhibition values within biological replicate 3. - Dataset (ID:20247)